Abstract Library

#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms

Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jann H

Authors: Schenk J, Kayser A, Wiedenmann B, Tacke F, Roderburg C,

Keywords: NEN G3, Chemotherapy, Platinum, NEC G3, NET G3,

#2294 Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors

Introduction: Neuroendocrine tumours (NETs) have been found to overexpress somatostatin receptors (SSTRs), which led to the development of somatostatin analogs utilized for diagnostics and therapeutics. However, around 30% of all NETs do not respond to somatostatin based approaches, leading to an interest to find and characterize alternative cell surface targets.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Wiedenmann B,

Keywords: AGTR1, PRRT, autoradiography, radioligand binding assay,

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Prasad V, Erdmann S, Wiedenmann B,

Keywords: PRRT,

#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens

Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dal Buono A

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: well-differentiated, platinum, streptozotocin,

#1540 FOLFOX Chemotherapy: Efficacy and Tolerability in Advanced Digestive Neuroendocrine Neoplasms (NENs)

Introduction: FOLFOX has been poorly investigated in digestive NEN (DNENs), mostly in small cohorts.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: FOLFOX, tolerability, tumor response.,